Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study
- 518 Downloads
Positive surgical margins remain a significant challenge in breast cancer surgery. This report describes the use of a novel, first-in-human ratiometric activatable cell-penetrating peptide in breast cancer surgery.
A two-part, multi-institutional phase 1 trial of AVB-620 with a 3+3 dose escalation and dose-expansion cohorts was conducted. The patients received an infusion of AVB-620 2–20 h before planned lumpectomy/mastectomy and sentinel node biopsy/axillary dissection. Imaging analysis was performed on images obtained from the surgical field as well as post-excision surgical specimens. Pathology reports were obtained to correlate imaging results with histopathologic data. Information on physical adverse events and laboratory abnormalities were recorded.
A total of 27 patients received infusion of AVB-620 and underwent surgical excision of breast cancer. The findings showed no adverse events or laboratory values attributable to infusion of AVB-620. The 8-mg dose was selected from the dose-escalation cohort for use with the expansion cohort based on imaging data. Region-of-interest (ROI) imaging analysis from the 8-mg cohort demonstrated measurable changes between pathology confirmed tumor-positive and tumor-negative tissue.
Intraoperative imaging of surgical specimens after infusion with AVB-620 allowed for real-time tumor detection. Infusion of AVB-620 is safe and may improve intraoperative detection of malignant tissue during breast cancer operations.
The authors acknowledge the Clinical Trials Office at Moores Cancer Center for their administrative oversight. Avelas Biosciences, Inc. paid for the clinical trial and administrative support.
Steven L. Chen, Jesús E. González, and Alec Harootunian are employees of Avelas Biosciences, Inc and have financial stock options. Jonathan T. Unkart, Irene L. Wapnir, and Anne M. Wallace have no disclosures.
- 5.Schulman AM, Mirrielees JA, Leverson G, Landercasper J, Greenberg C, Wilke LG. Reexcision surgery for breast cancer: an analysis of the American Society of Breast Surgeons (ASBrS) MasterySM Database following the SSO-ASTRO “no-ink-on-tumor” guidelines. Ann Surg Oncol. 2017;24:52–8.Google Scholar
- 7.Whitley MJ, Cardona DM, Lazarides AL, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016;8:320ra4. doi: 10.1126/scitranslmed.aad0293.
- 11.Miampamba M, Liu J, Harootunian A, et al. Sensitive in vivo visualization of breast cancer using ratiometric protease-activatable fluorescent imaging agent, AVB-620. Theranostics (in press). doi: 10.7150/thno.20678.
- 13.Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell-penetrating peptides for targeting protease activity in cancer. Integr Biol. 2009;1:382–93.Google Scholar